

Amaury Daste

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/297439/publications.pdf>

Version: 2024-02-01

31
papers

707
citations

687335

13
h-index

610883

24
g-index

31
all docs

31
docs citations

31
times ranked

1175
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune checkpoint inhibitors and elderly people: A review. <i>European Journal of Cancer</i> , 2017, 82, 155-166.	2.8	148
2	Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>European Journal of Cancer</i> , 2019, 121, 123-129.	2.8	115
3	A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. <i>European Journal of Cancer</i> , 2017, 76, 110-117.	2.8	89
4	Bintrafusp alfa, a bifunctional fusion protein targeting TGF- β 2 and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. , 2020, 8, e000664.		48
5	Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. <i>European Journal of Cancer</i> , 2021, 157, 474-484.	2.8	45
6	Targeted therapy and elderly people: A review. <i>European Journal of Cancer</i> , 2016, 69, 199-215.	2.8	34
7	A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The 11 cohort of the EORTC-HNCG-1559 UPSTREAM trial. <i>European Journal of Cancer</i> , 2021, 158, 17-26.	2.8	33
8	Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review. <i>European Journal of Cancer</i> , 2021, 158, 47-62.	2.8	32
9	Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6015-6015.	1.6	23
10	<p>Management of Immune Checkpoint Inhibitor Toxicities</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9139-9158.	1.9	18
11	Progression beyond nivolumab: Stop or repeat? Dramatic responses with salvage chemotherapy. <i>Oral Oncology</i> , 2018, 81, 116-118.	1.5	17
12	Current management and future perspectives of penile cancer: An updated review. <i>Cancer Treatment Reviews</i> , 2020, 90, 102087.	7.7	16
13	Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected response. <i>BMC Cancer</i> , 2017, 17, 323.	2.6	14
14	Immunotherapy in head and neck cancer: Need for a new strategy? Rapid progression with nivolumab then unexpected response with next treatment. <i>Oral Oncology</i> , 2017, 64, e1-e3.	1.5	13
15	The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours. <i>Acta Oncol&sup3gica</i> , 2021, 60, 1597-1603.	1.8	13
16	Treatment of spinal metastases in renal cell carcinoma: A critical review. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 125, 19-29.	4.4	12
17	Efficacy and safety of immune checkpoint inhibitors in elderly patients (³70 years) with squamous cell carcinoma of the head and neck. <i>European Journal of Cancer</i> , 2021, 157, 190-197.	2.8	6
18	Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME. <i>Cancer Medicine</i> , 2021, 10, 3952-3963.	2.8	5

#	ARTICLE	IF	CITATIONS
19	Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- β 2 and PD-L1, in advanced squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology, 2021, 39, 6020-6020.	1.6	4
20	Drug Interaction With Sunitinib and the Evidence of Therapeutic Drug Monitoring: A Case Report and Review of the Literature. Clinical Genitourinary Cancer, 2017, 15, e885-e887.	1.9	3
21	Induction chemotherapy with the EXTREME regimen in frail patients with locally advanced head and neck squamous cell carcinoma. Targeted Oncology, 2018, 13, 247-252.	3.6	3
22	Dramatic response after anti PD1 treatment failure in a squamous cell carcinoma of the maxillary sinus. Oral Oncology, 2018, 87, 207-209.	1.5	3
23	Prognostic factors for cancer patient admitted to a medical intensive care unit. Acta Oncol ³ gica, 2020, 59, 458-461.	1.8	3
24	m-TOR inhibitor as potential radiosensitizer for head and neck squamous cell carcinoma: A case report of an organ transplant patient and review of the literature. Oral Oncology, 2016, 62, e1-e2.	1.5	2
25	Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study. European Journal of Cancer, 2017, 85, 39-48.	2.8	2
26	The interest of sequential treatment with immune check point inhibitors followed chemotherapy: A case report. Oral Oncology, 2019, 94, 125-127.	1.5	2
27	Pulmonary Aspergilloma: An Unexpected Complication of Radiofrequency Ablation in the Management of Targeted Therapy for a Patient With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2014, 12, e115-e116.	1.9	1
28	Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the Literature. Clinical Genitourinary Cancer, 2016, 14, e525-e527.	1.9	1
29	Pulmonary arterial hypertension due to an intratumoral shunt: an unexpected side effect of sunitinib. Future Oncology, 2017, 13, 1219-1221.	2.4	1
30	Colitis presenting 5 months after the final dose of anti-PD-1: long-term monitoring is warranted after adjuvant therapy. Immunotherapy, 2021, 13, 741-744.	2.0	1
31	Dramatic response under combination of immune-oncology in head & neck cancer included in the Condor study: A case report. Oral Oncology, 2019, 89, 150-152.	1.5	0